The decision to tell or not to tell is associated with experiences of stigma and hearing aid use among adults with hearing loss.

Objectives: To explore the extent to which an international sample of adults with hearing loss experience and respond to stigma-induced identity threat; and the associations between experiences of hearing loss stigma, responses to hearing loss stigma (concealment of hearing loss), and hearing aid use.

Design: Cross-sectional online survey comprising published questionnaires and multiple response questions designed to capture five of seven constructs of the Major and O'Brien model of stigma-induced identity threat. Multivariate modelling examined factors associated with hearing aid use and concealment of hearing loss.

Huge extrahepatic gallstone on percutaneous transhepatic biliary drainage tip-a pediatric case report.

Biliary strictures, which are common in the first year after pediatric liver transplantation, are diagnosed and managed with percutaneous transhepatic cholangiography. In children undergoing percutaneous transhepatic cholangiography, early cholangitis is the most common complication while typical catheter-related complications are obstruction, dislodgement, kinking, or fracture. This case report discusses the unique presentation and management of a 5-year-old girl with an incidental percutaneous transhepatic biliary drainage-associated extrahepatic gallstone formation following treatment of biliary stricture after pediatric liver transplantation.

App-Based Coaching to Prevent Addictive Behaviors in Vocational School Students: A Cluster Randomized Trial.

Purpose: This two-arm cluster randomized controlled trial evaluated the effectiveness of an app-based addiction prevention program in German vocational school students.

Methods: Schools from 5 German federal states were recruited. No eligibility criteria for classes were applied; enrollment decisions were made by school heads or teachers.

Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study.

Introduction: This was the first phase 1 study conducted in the United States. It consisted of dose-escalation (part A) and multiple indication-specific cohort expansion (part B), investigating the safety and preliminary efficacy of toripalimab (anti-programmed cell death-1 inhibitor) in patients with advanced malignancies.

Methods: Patients with advanced malignancies that progressed after treatment with at least one prior line of standard systemic therapy, including the patients with advanced/recurrent cholangiocarcinoma (CCA), received toripalimab 240 mg every 3 weeks in part B.